Amlogenyx
Amlogenyx Inc., a subsidiary of Ultragenyx Pharmaceutical, Inc., is focused on researching and developing novel gene therapies for Alzheimer's disease and other amyloid diseases. Their lead product candidate is a protease designed to break down Aβ42, a protein believed to be responsible for Alzheimer's debilitating effects.
Funding Round: Seed
Funding Amount: $14M
Date: 02-Aug-2024
Investors: GordonMD ® Global Investments LP, Ultragenyx
Markets: Biotechnology, Gene Therapy, Pharmaceuticals, Genetics, Therapeutics
HQ: Somerville, Massachusetts, United States
Founded: 2023
Website: https://www.amlogenyx.com
Crunchbase: https://www.crunchbase.com/organization/amlogenyx
Leave a Comment
Comments
No comments yet.